FDAsafety guidance83% confidence
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Janssen.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · CAR T-cell Therapy
- Sub-indication
- General
Related signal: Phase 1b/2 Study of JNJ-90014496 for B-Cell Non-Hodgkin Lymphoma Initiated by Janssen